Menu
  • The inaugural holding of the US E-Cigarette Summit will take place in Washington DC, on Monday May 8, 2017
  • Registration for the US E-Cigarette Summit 2017 is now open

 

2017 Speakers

Prof Thomas J. Glynn, PhD
Prof Thomas J. Glynn, PhD

Consulting Professor, Stanford Prevention Research Centre, Stanford University School of Medicine

Thomas J. Glynn, PhD is currently Consulting Professor, Stanford Prevention Research Center, Stanford University School of Medicine, in Palo Alto, California. From 1998 to 2014, he was Director, Cancer Science and Trends and Director, International Cancer Control at the American Cancer Society (ACS), in Washington, DC. In these positions, he advised the ACS about emerging research and policy issues in tobacco/cancer prevention and control, recommended tobacco/cancer prevention and control research and policy which is ready for national/global application, and participated in the development of an international cancer control program aimed at promoting tobacco and cancer prevention-related research, advocacy, treatment, and policy change, particularly in middle- and low-income nations.

Prior to coming to the ACS, Dr. Glynn was, from 1991 to 1994, Associate Director of the U.S. National Cancer Institute’s (NCI) Cancer Control Science Program and, from 1991 to 1998, Chief of the NCI’s Cancer Control Extramural Research Branch. There, he directed the development of a national program of research aimed at reducing the incidence and prevalence of cancer, primarily through dietary change, tobacco use reduction, and adherence to cancer screening guidelines. From 1983 to 1991, he was Research Director for the NCI’s Smoking, Tobacco, and Cancer Program.

Dr. Glynn is widely published on cancer and tobacco use prevention and control, both in the scientific literature and for consumer, professional, and patient education audiences. He has served as a consultant on cancer control and tobacco issues to such groups as the National Academy of Sciences/Institute of Medicine, the National Research Council, the Robert Wood Johnson Foundation, Mayo Clinic, and state and local governments, as well as a wide range of international organizations. He has also served as a Senior Scientific Reviewer for many U.S. Surgeon General’s Reports on Tobacco and Health, as Director of the World Health Organization Study of Health, Economic, and Policy Implications of Tobacco Growth and Consumption in Developing Countries, and has been active in tobacco control programs in Eastern Europe, Central America, and India. His awards include the U.S. National Institutes of Health Merit Award, the Polish Ministry of Health Service Award, the Guatemala National Council for Tobacco Prevention and Control Meritorious Service Award, the American Society of Preventive Oncology Joseph W. Cullen Memorial Award, and the SRNT’s John Slade Award.

 

Prof Kenneth E. Warner
Prof Kenneth E. Warner

Avedis Donabedian Distinguished University Professor of Public Health, University of Michigan

Kenneth E. Warner is the Avedis Donabedian Distinguished University Professor of Public Health and Professor of Health Management and Policy at the University of Michigan School of Public Health, where he has been on the faculty since 1972.  He served as Dean of the School of Public Health from 2005-2010.  An economist, Dr. Warner earned his A.B. degree summa cum laude from Dartmouth College in 1968 and M.Phil. and Ph.D. degrees from Yale University in 1970 and 1974, respectively.

Presented in over 200 professional publications, Dr. Warner’s research has focused on economic and policy aspects of disease prevention and health promotion, with a special emphasis on tobacco and health.  Dr. Warner served as the World Bank’s representative to negotiations on the global treaty on tobacco control, the Framework Convention on Tobacco Control. He also served as the Senior Scientific Editor of the 25th anniversary Surgeon General’s report on smoking and health, published in 1989.  He has chaired the Editorial Advisory Board of the international journal Tobacco Control since the journal’s inception in 1992. During 2004-05 he was President of the Society for Research on Nicotine and Tobacco. He consults with numerous governmental bodies and voluntary organizations, and was a founding member of the Board of Directors of the American Legacy Foundation (now the Truth Initiative). He was also the founding Director of the University of Michigan Tobacco Research Network.  Dr. Warner has testified before the U.S. Senate and the House of Representatives.

Dr. Warner has been cited twice by Delta Omega, the national public health honorary society, for “Outstanding Achievement in Public Health.”  He was awarded the Surgeon General’s Medallion by Dr. C. Everett Koop in 1989.  In 1990, he received the Leadership Award of the Alcohol, Tobacco, and Other Drugs Section of the American Public Health Association.  In 1996, he was elected to membership in the Institute of Medicine (now the National Academy of Medicine) of the National Academy of Sciences and was named to the first class of Fellows of the Association for Health Services Research (now AcademyHealth).  In 1997, he received the Excellence in Research Award from the University of Michigan School of Public Health.  In 2002 he received the Richard and Barbara Hansen Leadership Award from the University of Iowa College of Public Health.  In 2003, at the World Conference on Tobacco or Health in Helsinki, Finland, he received the inaugural Outstanding Research Contribution award in the international Luther L. Terry Awards for Exemplary Leadership in Tobacco Control.  In 2006 he was selected as an Ambassador in the Paul G. Rogers Society for Global Health Research, Research!America.  In 2010 he received the Alton Ochsner Award Relating Smoking and Health.  In 2013 he received the University of Michigan School of Public Health Excellence in Teaching Award. In 2014 Dr. Warner was awarded a Regional World No Tobacco Day Award by the World Health Organization/Pan American Health Organization. In March 2017 he will receive the Doll-Wynder Award from the Society for Research on Nicotine and Tobacco in Florence, Italy.

Asst. Prof Samir Soneji
Asst. Prof Samir Soneji

Assistant Professor, The Dartmouth Institute for Health Policy and Clinical Practice

Samir S. Soneji is an Assistant Professor at the Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Dartmouth College. He is also a member of the Cancer Control Program at the Norris Cotton Cancer Center and The C. Everett Koop Institute at Dartmouth. His research interests include adolescent and young adult tobacco use and tobacco regulatory control.screening. Samir received his PhD in Demography from Princeton University in 2008. He also holds a MA in Statistics from Columbia University, a BS in Mathematics from the University of Chicago, and served as a Captain in the US Air Force. He was formerly a Robert Wood Johnson Health and Society Scholar at the University of Pennsylvania.

Professor Linda Bauld
Professor Linda Bauld

Professor of Health Policy, University of Stirling, UK Centre for Tobacco and Alcohol Studies (UKTAS) and Cancer Research UK

Linda Bauld is Professor of Health Policy, Director of the Institute of Social Marketing and Dean of Research Impact at the University of Stirling. She is also a Deputy Director of the UK Centre for Tobacco and Alcohol Studies and holds the CRUK/BUPA Chair in Behavioural Research for Cancer Prevention at Cancer Research UK. She has conducted applied research on tobacco control and smoking cessation for 20 years, is a former scientific adviser on tobacco control for the UK government, Deputy Editor of the journal Nicotine and Tobacco Research and President-elect of the Society for Research on Nicotine and Tobacco Europe. She chaired the NICE programme development group on tobacco harm reduction and is involved in ongoing research on this topic. In 2017 she was elected a Fellow of the Royal College of Physicians of Edinburgh for her work in cancer prevention and public health.

Competing Interest: None Stated

Andrea Villanti, PhD, MPH
Andrea Villanti, PhD, MPH

Director of Regulatory Science and Policy, Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative and Associate Professor, Dept Psychiatry at University of Vermont

Andrea Villanti, Ph.D., M.P.H., is Director for Regulatory Science and Policy at the Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative and Associate Professor in the Department of Psychiatry, Vermont Center on Behavior & Health, at the University of Vermont. She also holds an adjunct faculty appointment at the Johns Hopkins Bloomberg School of Public Health.

Dr. Villanti’s primary focus is on translational research to improve tobacco control policy and program decision-making, including tobacco regulatory science. Her area of expertise is in young adult tobacco use. She is the Principal Investigator on Truth Initiative’s Young Adult Cohort Study and has a two-year study, funded by the National Cancer Institute to examine social smoking in young adults. She is also a collaborating research scientist on a five-year study, funded by the National Institute on Drug Abuse and the Food and Drug Administration, to examine the impact of FDA regulations on tobacco products.

She received her doctorate in social and behavioral sciences from the Johns Hopkins University and her master’s in public health degree from Columbia University.

 

Dr Robin Mermelstein
Dr Robin Mermelstein

Professor of Psychology and IHRP Director, University of Illinois, Chicago

Dr. Robin Mermelstein, a professor of psychology and distinguished professor of the College of Liberal Arts and Sciences, directs the Institute for Health Research and Policy at the University of Illinois at Chicago. She also is a clinical professor of community health sciences in the UIC School of Public Health, an assistant dean of the UIC College of Medicine, and the co-principal director of the UIC Center for Clinical and Translational Science.  Her research interests fall broadly in the area of tobacco use, with studies ranging from longitudinal examinations of the etiology of youth smoking to cessation interventions for adult smokers.

Since the mid 1990s, Dr. Mermelstein has been the principal investigator of a series of studies, including two consecutive program projects funded by the National Cancer Institute, to investigate trajectories of smoking patterns among adolescents and young adults, with a focus on social and emotional contextual factors.
In addition, she has been funded by the Centers for Disease Control and Prevention to examine factors related to youth smoking, and by the National Heart, Lung, and Blood Institute and NCI for studies of adult smoking cessation. Other areas of research focus include health behaviors of young adults and motivational interventions to increase smoking cessation.

Dr. Mermelstein is the past-president of the Society for Research on Nicotine and Tobacco and serves on national research review committees of the National Institutes of Health. She served on the Institute of Medicine committee that wrote the 2015 consensus study report, Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products.

She directed the Robert Wood Johnson Foundation’s national program office of Partners with Tobacco Use Research Centers: A Transdisciplinary Approach to Advancing Science and Policy Studies. As part of this program, RWJF collaborated with both NCI and the National Institute on Drug Abuse in funding the Transdisciplinary Tobacco Use Research Centers.In 2014, the University of Illinois at Chicago named Dr. Mermelstein Woman of the Year for her contributions to women’s health and professional development.

Brian Carter PhD
Brian Carter PhD

Volunteer - Director of Scientific Communications, CASAA

Brian Carter PhD, Director of Scientific Communications of CASAA, graduated from Purdue University in 1999 with a PhD in clinical psychology.  Elected to the Board of Directors in 2015, Dr. Carter has a scientific background in nicotine and tobacco research.  As a former faculty member in the Department of Behavioral Science at the University of Texas M.D. Anderson Cancer Center, he conducted multiple National Cancer Institute funded laboratory studies on the emotional, genetic, physiological, and behavioral aspects of nicotine use in cigarette smokers. He prepares science-based materials on smoke-free alternatives for CASAA members and the public at large; he also represents CASAA at national and international conferences on tobacco harm reduction.

Dr Judith Prochaska PhD, MPH
Dr Judith Prochaska PhD, MPH

Associate Professor of Medicine, Stanford University

Judith (Jodi) Prochaska, PhD, MPH is Associate Professor of Medicine with the Stanford Prevention Research Center and a member of the Stanford Cancer Institute.  Dr. Prochaska’s clinical trials research leverages technology to address tobacco use in ethnically diverse and disenfranchised groups. Current research funding agencies include NHLBI, NCI, NIDA, and the State of California Tobacco Related Disease Research Program. Dr. Prochaska has reported on online patient-doctor communications regarding use of e-cigarettes (AJPM 2016) and led development of Stanford’s free online CME on electronic nicotine delivery systems https://med.stanford.edu/cme/courses/online/e-cig.html. Globally, she has disseminated tobacco treatment curricula as part of Rx for Change (http://rxforchange.ucsf.edu).

Dr. Prochaska is President of the Society for Research on Nicotine and Tobacco (SRNT), she has authored 175 peer-reviewed publications, and serves on the Editorial Board of JAMA Internal Medicine.

Dr. Raymond Niaura, PhD
Dr. Raymond Niaura, PhD

Director, Science and Training, Schroeder Institute for Tobacco Research and Policy Studies

Raymond Niaura, Ph.D., is director of Science at the Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative, where he also oversees the pre- and post-doctoral training program. He is an adjunct professor in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health and an adjunct professor at the Georgetown University Medical Center.

Dr. Niaura has been awarded numerous grants from the National Institutes of Health, several foundations and private industry for his research work. His focus is the study of combined pharmacological and behavioral treatments to aid smoking cessation, with a particular interest in cessation in disadvantaged populations.

He has published more than 300 peer-reviewed papers, is deputy editor of Nicotine and Tobacco Research, and has authored several individual book chapters as well as co-authored the book “The Tobacco Dependence Treatment Handbook: A Guide to Best Practices.” He is a past president of the Society for Research on Nicotine and Tobacco.

Dr. Niaura received his doctorate from Rutgers University.

Professor Neal L. Benowitz MD
Professor Neal L. Benowitz MD

Professor of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco

Neal L. Benowitz, MD, is Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969, following which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 500 research papers. Dr Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology.

Dr Benowitz was a scientific editor of the 1988 United States Surgeon General’s Report on Smoking and Health: Nicotine Addiction; a scientific editor of the 2001 NCI Monograph 13 Report on Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine; and served as section editor for the 2010 Surgeon General’s Report on How Tobacco Smoke Causes Disease. He,has served as a member of the National Institutes of Health Pharmacology Study Section, the FDA Nonprescription Drug Advisory Committee and the FDA Tobacco Products Science Advisory Committee. He is a member of a number of medical societies, including the American Society for Clinical Investigation and the Association of American Physicians. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.

 

Prof Jonathan Foulds
Prof Jonathan Foulds

Professor of Public Health Sciences and Psychiatry, Penn State Tobacco Center of Regulatory Science, Cancer Institute

Jonathan Foulds, PhD. is a Professor of Public Health Sciences and Psychiatry at Penn State University, College of Medicine. After obtaining a first class honors degree in psychology at University of Aberdeen in Scotland, he trained as a clinical psychologist at the University of Glasgow, and then spent most of his career developing and evaluating methods to help smokers beat their addiction to tobacco. He obtained his PhD at the Institute of Psychiatry, University of London and worked at St George’s Hospital Medical School as the UK’s first “lecturer in tobacco addiction”. He then moved to University of Surrey and continued to work as a principal clinical psychologist at Broodmoor Hospital, a large maximum security facility for mentally disordered offenders.

Jonathan was on the Management Group of the Hungarian Anti-Smoking Campaign (1995-6), has been a technical leader of a World Health Organization project to improve the regulation of tobacco dependence treatment in Europe (2000), and was Director of Research for the UK charity, Quit, which ran the largest telephone helpline for smokers in the world at that time. From 2000-2010 he was the director of the Tobacco Dependence Program at the University of Medicine & Dentistry of New Jersey (now Rutgers)– School of Public Health. Although primarily funded for service and training activities, TDP program members published over 90 articles on tobacco during that period. He was a founding member and Vice President of the Association for the Treatment of Tobacco Use and Dependence (ATTUD) 2004-6. In the USA he has been a principal investigator on grants totaling well over $27 million, and has been invited to speak on smoking cessation in over 15 countries. Dr. Foulds acts as a Health Expert on the www.WebMD.com Smoking Cessation Community. He has published over 100 papers on tobacco in peer-reviewed scientific journals and continues to treat addicted smokers, teach on smoking cessation and conduct research on tobacco and health at Penn State College of Medicine in Hershey, PA.

Dr Konstantinos Farsalinos M.D
Dr Konstantinos Farsalinos M.D

Research Fellow, Onassis Cardiac Surgery Greece, Department of Pharmacology, University of Patras, Greece

Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens, Greece, and at the Department of Pharmacy, University of Patras, Greece. He has been conducting laboratory and clinical research on e-cigarettes as a principal investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has presented his research findings at major international scientific congresses and his research was used in preparing the regulatory framework on e-cigarettes by the European Union. As of April 2017, he has published more than 50 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes. He was also the handling editor and author in a book titled “Analytical assessment of e-cigarettes”, published by Elsevier.

Competing Interest: For some of the studies, the institution has received funding from e-cigarette companies. None of the researchers received any compensation for participating to the studies.

Jennifer Berger-Coleman
Jennifer Berger-Coleman

Vaper/Volunteer, CASAA

Jennifer Berger-Coleman, Director of Community Outreach, a Certified Medical Assistant, has worked in the medical field since 2006. She is currently employed at California State University – Sacramento, and worked at a national women’s health organization for several years prior, during which time she served as the outreach coordinator, planning weekend events to bring education about safer sex to the streets and bars of Sacramento. She also volunteered her time during those years to do outreach and attend city council meetings for Equality California (EQCA), as well as Safe Ground Sacramento (an advocacy organization for the homeless population). After quitting a 25-year, pack-a-day smoking habit in June 2015 using vapor products, she became a passionate advocate for tobacco harm reduction and consumer choice.

Prof. Joanna Cohen PhD
Prof. Joanna Cohen PhD

Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control, Johns Hopkins Bloomberg School of Public Health

Joanna Cohen is the Bloomberg Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control at the Johns Hopkins Bloomberg School of Public Health.

Dr. Cohen obtained her PhD in Health Policy and Administration from the University of North Carolina – Chapel Hill and her MHSc in Community Health and Epidemiology from the University of Toronto. She has been involved in tobacco policy research for over 20 years.

Trained in epidemiology and health policy, her research interests focus on the factors that affect the adoption and implementation of public health policies and on evaluating the beneficial effects and the unintended consequences of such policies. She has worked on studies of both US and Canadian legislators regarding tobacco and tobacco control policy, a longitudinal cohort of smokers focusing on factors influencing quitting behavior, tobacco promotion at the point of sale, tobacco prices including taxes, tobacco packaging, options for reducing the physical availability of tobacco products, and tobacco industry interference in tobacco control.

Dr. Cohen has been recognized for her teaching and mentoring, and has co-led a 6-year training program in public health policy.

She is the Deputy Editor of Tobacco Control and was recently a voting member of the U.S. Food and Drug Administration’s Tobacco Product Scientific Advisory Committee.

Matthew L. Myers
Matthew L. Myers

President, Campaign for Tobacco-Free Kids

Matthew L. Myers is President of the Campaign for Tobacco-Free Kids, a leader in the fight to reduce tobacco use and its devastating consequences in the United States and around the world.

In 1996, Mr. Myers helped to found the Campaign for Tobacco-Free Kids and has been with the Campaign since its inception. Initially, he served as its Executive Vice President and Legal Counsel and oversaw the Campaign’s legal and advocacy efforts. On January 1, 2000, Mr. Myers became the Campaign’s President.

In his position at the Campaign Mr. Myers helped to lead the Campaign’s effort to defend FDA’s assertion of jurisdiction over cigarettes and smokeless tobacco products in 1996.  Mr Myers then served as a close advisor to the State Attorneys General in the 1990s when they sued the tobacco industry.

He participated in the 1996 negotiations that led to the first ever settlement with a tobacco company, Liggett and Myers, an agreement that broke the tobacco industry’s unity and resulted in the release of a massive amount of previously secret tobacco industry documents.

In 1997, at the request of the State Attorneys General and the White House, Mr. Myers participated in the negotiations that led to the unprecedented agreement between the tobacco industry and the states in June 1997. He then served as one of the leading spokespersons for the legislative debate related to that settlement that followed in Congress.

Mr. Myers subsequently advised a number of State Attorneys General during the negotiations that led to the Master Settlement Agreement in 1998 and oversaw the Campaign’s effort to get the states to use Master Settlement Agreement funds for comprehensive tobacco control.

Since that time under Mr. Myers’ leadership the Campaign has been a leader in the effort to raise tobacco taxes, expand protection against secondhand smoke and fund effective comprehensive tobacco control programs at the state level

Deborah Arnott
Deborah Arnott

Chief Executive, Action on Smoking and Health (ASH)

Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the NICE Programme Development Group which developed the guidance on tobacco harm reduction and of the Commission on Human Medicines expert advisory group to the MHRA on nicotine containing products.  She also has experience of product regulation under the EU General Product Safety Directive having participated in the development of fire safety requirements for cigarettes.

Deborah has an MBA from Cranfield, is an honorary Associate Professor at the University of Nottingham, and a member of the Royal College of Physicians Tobacco Advisory Group.  She was awarded the Alwyn Smith prize in 2007 by the Faculty of Public Health for her outstanding contribution to public health.

Competing Interest: None Stated

Dr. Kevin Walton PhD
Dr. Kevin Walton PhD

Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences, (NIDA) National Institute on Drug Abuse, NIH

Dr. Kevin Walton is the Chief of the Clinical Research Grants Branch in the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse at the National Institutes of Health. His branch is responsible for leading the grant-funded clinical research exploring new medication, behavioral, and device development for the treatment of substance use disorders, including smoking cessation. After a position as an Assistant Professor at the University of Michigan, Dr. Walton spent 15 years in neuroscience drug discovery in the biotech and pharmaceutical industries where he worked on developing novel medications for both neurological and psychiatric disorders.  He has been at NIH since 2010 and joined NIDA in 2013. Dr. Walton received his PhD in Pharmacology at the Johns Hopkins University School of Medicine.

David Graham
David Graham

President & Managing Partner, Reveritas Group

David Graham is President and Managing Partner of Reveritas Group, a multi-partner regulatory, clinical, and scientific consulting firm supporting ENDS companies in their efforts to comply with FDA regulations, with a current focus on plan development and execution of programs for Premarket Tobacco Applications (PMTA) to FDA. He also has a leadership role at GoodCat Laboratories, an ISO 17025 ALA accredited analytical test laboratory and OEM manufacturer of e-liquid for multiple ENDS companies, where he is overseeing the upscale of its production and analytical testing to meet demand for quality focused e-liquid and aerosol testing services. David also supports continuing program work on a National Institute of Drug Abuse (NIDA)-funded Small Business Innovation Research (SBIR) award to NJOY to develop a standardized research ENDS product for use for clinical research to evaluate ENDS for smoking cessation and risk reduction. (Currently the subject of a NIDA Funding Opportunity Announcement (FOA) that aims to evaluate ENDS effects on multiple behavioral and health biomarkers in current tobacco smokers and inform e-cigarette public health policy decision-making.)

David has unparalleled experience in nicotine related new product development, tobacco control policy, and related regulation in the healthcare and electronic nicotine delivery sectors spanning ~ 25 years. Beginning his work related to ENDS in 2013, David joined NJOY to lead the regulatory affairs, quality & compliance function for the company to develop its regulatory strategy and prepare for regulation, where he created and managed submissions related to FDA regulatory rule-making consultations, supported new product planning and development, and coordinated multiple meetings with FDA’s Office of the Director and Office of Science as well as other government agencies in the US and abroad. Previously, at Johnson & Johnson, Pfizer, and Pharmacia, David was instrumental in securing support and regulatory approval for new nicotine replacement therapy (NRT) products, access channels, and expanded indications in multiple countries, where he held various Vice President and Senior Director roles directing global public policy, tobacco dependence category and product development, and marketing for the Nicorette brand internationally. During this time David jointly established multiple ground-breaking public private partnerships with national governments, NGOs, and intergovernmental organizations including the World Health Organization in efforts to reduce the death and disease caused by smoking.

David is a graduate of Columbia University with a Master of Public Policy & Administration (MPA).

Eric N. Lindblom JD
Eric N. Lindblom JD

Program Director, Tobacco Control and Food and Drug Law, O’Neill Institute for National and Global Health Law, Georgetown University Law Center

Eric N. Lindblom, JD, is the Director for Tobacco Control and Food and Drug Law at the O’Neill Institute for National and Global Health Law.  Mr. Lindblom was the Director of the Office of Policy at the FDA’s Center for Tobacco Products from 2011-2014, and previously served as General Counsel and Director for Policy Research at the Campaign for Tobacco-Free Kids, where he began work in 1998.  Mr. Lindblom has extensive experience analyzing and evaluating different tobacco control policies in the U.S. and overseas; and is the author of “Effectively Regulating E-Cigarettes and their Advertising – and the First Amendment” (Food & Drug Law Journal, 2015).

Besides supporting public health litigation relating to regulated products, Mr. Lindblom works with tobacco control and other regulatory and public health researchers to help make their research more policy relevant and influential by providing the legal and policy contexts for their research in related proposals, project designs, and publications. To accelerate the development of new legal and policy analyses to inform the regulation of tobacco products, foods, and drugs (including legalized cannabis), Mr. Lindblom also works through the O’Neill Institute to convene diverse groups of relevant experts at Georgetown University’s law school to consider key issues, questions and strategies, and to develop reports and other publications presenting the related consensus analyses, answers, and recommendations.

Prof John R Hughes
Prof John R Hughes

Professor of Psychiatry and Psychological Science, University of Vermont

John R. Hughes, M.D. is Professor of Psychiatry and Psychological Science at the University of Vermont.  Dr. Hughes is board certified in Psychiatry and Addiction Psychiatry.  He is  co-founder and past president of the Society for Research on Nicotine and Tobacco, and the Association for the Treatment of Tobacco Use and Dependence.  Dr. Hughes received the Ove Ferno, Alton Ochsner and the ATTUD Excellence in Tobacco Treatment, Training and Advocacy Awards. Dr. Hughes has been Chair of the Vermont Tobacco Evaluation and Review Board which oversees VT’s multi-million dollar tobacco control program.  He has over 450 publications on nicotine and other drug dependencies

 

Professor Ann McNeill
Professor Ann McNeill

Professor of Tobacco Addiction, UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London

Ann McNeill is a Professor of Addictions in the National Addiction Centre with a focus on tobacco. She graduated from the University of Nottingham with a first class joint honours degree in zoology and psychology and then carried out her PhD at the Institute of Psychiatry focusing on the development of dependence on smoking. Since that time she has held a variety of academic and public sector posts focusing largely on tobacco control research. Ann has an established international reputation, receiving a World Health Organisation award for contributions to tobacco control in 1998.

She has published more than 250 academic papers book chapters, reports and opinion pieces on the subject and her research ranges across prevention, cessation, harm reduction and local, national and international policy. Ann was a co-author of the recent systematic review of tobacco product packaging which underpinned the recent government consultation on plain packaging and has a particular interest in the relationship between smoking, mental health and inequalities. She is Deputy Director of the UK Centre for Tobacco Control Studies.

Competing Interest: None Stated

Prof Dorothy Hatsukami
Prof Dorothy Hatsukami

Associate Director of Cancer Prevention and Control, Masonic Cancer Center, University of Minnesota

Dorothy Hatsukami, Ph.D. is currently the Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota, a Forster Family Chair in Cancer Prevention, a Professor of Psychiatry and Adjunct Professor of Psychology and of Epidemiology at the University of Minnesota, and the Director of the Tobacco Research Programs.

Dr. Hatsukami is known for her research in the areas of nicotine addiction and treatment of nicotine addiction among a general population of adult smokers as well as adolescents. She has also conducted research in the area of smokeless tobacco. Her most recent research has primarily been focused on developing methods and measures to evaluate tobacco products and she has led an effort to develop a trandisciplinary team (both institutionally and nationally) around this topic. She has also concentrated her efforts on exploring and developing the science base for policies that might reduce tobacco-caused death and disease such as reducing the toxicity and nicotine in tobacco products.

Because of her expertise, Dr. Hatsukami has served on a number of national committees including the National Advisory Council for Substance Abuse and Mental Health Services Administration, National Advisory Council on Drug Abuse, the Interagency Committee for Smoking and Health, Drug Control Research, Data, and Evaluation Committee for the Office of National Drug Control Policy, the Institute of Medicine and on the Scientific Board of Counselors for the Intramural Research Program of NIDA. She has also served on the Tobacco Product Scientific Advisory Committee for the Food and Drug Administration. She has served on many advisory panels for other federal, non- profit and international organizations. She is a past president of the Society on Research on Nicotine and Tobacco and a past president of the College on Problems of Drug Dependence.

Attorney General Tom Miller
Attorney General Tom Miller

Attorney General of Iowa

Attorney General Tom Miller is serving in his ninth four-year term as Attorney General of Iowa. Tom Miller grew up in Dubuque, where his father was the long-time county assessor and an inspiration for Tom’s early interest in public service.  He graduated from Wahlert High School in 1962 and Loras College in 1966, and received his law degree from Harvard Law School in 1969. Mr. Miller has earned a reputation for integrity, high quality legal work, and strong work on behalf of ordinary Iowans.

Attorney General Miller is known for his long-time fight on behalf of kids and taxpayers with his campaign to reduce the enormous death toll and financial costs of tobacco addiction and disease.  He was a leader in the multistate settlement agreement that resulted in the tobacco industry paying billions of dollars to the states and changing the way it conducts business. Now Attorney General Miller is working to reduce youth addiction and the thousands of Iowans who die every year from tobacco-related disease.

Mr. Miller has a long record of achieving results through cooperation with other state attorneys general and with local, state and federal officials, regardless of their political affiliation.  He has served as President of the National Association of Attorneys General (NAAG) and received NAAG’s Wyman Award as the attorney general who contributed most to NAAG and its members.  He has chaired several NAAG committees and led major multistate working groups working on tobacco issues, antitrust enforcement, agriculture, and consumer protection.

“I consider it my duty and my privilege to be the people’s lawyer,” Attorney General Miller says. “I am deeply grateful for being able to serve as Attorney General of Iowa.”